# Understanding Schizophrenia: From Historical Roots to Contemporary Care

Jayarama Reddy[1], Dencita Vaz[1], Rakshith S[1], Charan Gowda[1], Kukkeshree Gowda[1] and Ashoka Hadagali[2*]

[1]St. Joseph's University, 36, Lalbagh Road, Bengaluru, Karnataka, India.

[2]B.M.S. College of Engineering, Bengaluru, Karnataka, India

## Abstract

**Schizophrenia is a complex psychiatric disorder that has intrigued researchers and clinicians for centuries. This research article delves into the origins and historical evolution of schizophrenia, its prevalence in different populations, the diverse range of symptoms it manifests, and the current treatment approaches available. Understanding these facets is crucial for improving diagnosis, management, and ultimately the quality of life for individuals affected by this challenging condition. Schizophrenia continues to pose significant clinical and societal challenges, necessitating ongoing research and collaborative efforts across disciplines. By advancing our understanding of its origins, prevalence, symptoms, and treatment, we can better support affected individuals and families, ultimately striving towards more effective interventions and improved mental health outcomes. Schizophrenia remains one of the most enigmatic and debilitating mental disorders, affecting approximately 1% of the global population. The lifetime risk of death by suicide in patients with schizophrenia is 5% to 10%. Despite therapeutic advancements, challenges such as medication non-adherence, side effects, and stigma associated with schizophrenia persist. Future research aims to refine diagnostic tools, personalize treatment strategies, and explore novel therapeutic targets to improve outcomes and quality of life for individuals living with schizophrenia.**

**Keywords:** anxiety, depression, mental disorder, schizophrenia, suicide.

*Corresponding author:
(Ashoka Hadagali)

## Introduction

Schizophrenia is a complex psychiatric disorder affecting about 1% of the global population, typically manifesting in late adolescence or early adulthood. Symptoms can include hallucinations, delusions, cognitive impairments, and social withdrawal, posing significant public health challenges due to the disorder's profound impact on individuals' lives and societal costs. Despite advancements in treatment, challenges such as medication non-adherence, side effects, and pervasive stigma persist.

The World Health Organization (WHO) highlights that schizophrenia causes psychosis and is associated with significant disability, affecting personal, family, social, educational, and occupational functioning. Stigma and discrimination are common, and more than two-thirds of people with psychosis globally do not receive specialized mental health care (World Health Organization (WHO))[1].

Cognitive impairments in schizophrenia, such as memory and attention deficits, often precede the illness and are considered stable rather than progressive. These impairments are strongly linked to social deficits and functional outcomes, impacting daily living tasks and rehabilitation[2].

This review aims to explore the multifaceted nature of schizophrenia by delving into its historical evolution, prevalence across different populations, the diverse range of symptoms it encompasses, and the current treatment approaches available. By advancing our understanding of these aspects, we can improve diagnosis, management, and ultimately, the quality of life for those affected by this condition. Furthermore, the review will highlight the importance of ongoing research and interdisciplinary collaboration in addressing the clinical and societal challenges posed by schizophrenia. Through these efforts, we strive to develop more effective interventions and achieve better mental health outcomes for individuals living with this enigmatic disorder.

## Age at onset distribution of Schizophrenia

Mental health is increasingly recognized as a priority in health policies globally and has been incorporated into the Sustainable Development Goals [3–5]. Schizophrenia remains one of the most enigmatic and debilitating mental disorders, affecting approximately 1% of the global population[6].

The difference in the age of onset of schizophrenia between sexes was first observed by Kraepelin. This finding has since become a well-established aspect of the disorder's epidemiology. Further

studies, including 7 on the age at onset and 13 on the age of first admission, consistently show that schizophrenia tends to appear earlier in men compared to women. Despite extensive research, its exact etiology remains elusive, contributing to the ongoing challenges in its diagnosis and treatment. The age of onset of the disorder is higher in males as compared to females (Figure 1). The study involved 123 men and 147 women. In Figure 1, circles represent males and triangles represent females, indicating the number of probands with onset age within the 5-year period centered on the specified age. Male cases were more frequent before age 30, while female cases were higher after 30. Both sexes experienced a rapid increase in cases in the late teens and early twenties, followed by a decline in the late twenties. The distributions were similar, but males had a higher peak. After age 40, cases declined gradually in both sexes, with the decline in women lagging 5-10 years behind men. A slight second peak was noted in women aged 30-40[7].




**Figure 1: Age at onset distribution of Schizophrenia in years**[7]

**Schizophrenia across nations**

At any given time, more than 3 million people in India suffer from schizophrenia. Bangladesh records highest rate of prevalence as shown in Figure 2. The bar graph shows the estimated share of people who had schizophrenia in the past year across several nations, with Bangladesh having the highest prevalence, followed by Austria, France, Germany, Colombia, and Sudan. This data is sourced from the Global Burden of Diseases, 2024[8]. The bar graph, sourced from the Global Burden of Diseases, 2024, illustrates the estimated prevalence of schizophrenia over the past year across several nations.

It shows that Bangladesh has the highest prevalence of schizophrenia, with approximately 750 people per million affected. Austria follows with about 600 people per million, while France has around 550 people per million. Germany reports about 450 people per million, Colombia has approximately 425, and Sudan, with the lowest prevalence among the listed countries, has about 350 people per million. The vertical axis of the bar plot represents the number of people affected per million, and the horizontal axis lists the countries. This plot highlights the significant differences in schizophrenia rates, with Bangladesh experiencing the highest prevalence.




**Figure 2: Estimated share of people who had schizophrenia in the past year in the nations with highest prevelance**[8]

Originally termed dementia praecox by Emil Kraepelin in the late 19th century, the disorder was later differentiated from other psychoses by Eugen Bleuler in the early 20th century[9]**.** Historical perspectives have shaped diagnostic criteria and treatment modalities, reflecting evolving societal attitudes towards mental illness. Schizophrenia exhibits a global distribution, although prevalence rates vary across different regions and demographic groups [10,11]. Factors such as genetic predisposition, environmental influences, and socio-economic status play significant roles in its incidence and prevalence. The hallmark symptoms of schizophrenia are categorized into positive symptoms (e.g., hallucinations, delusions), negative symptoms (e.g., social withdrawal, reduced emotional expression), and cognitive deficits (e.g., impaired executive function, attention deficits). Diagnosis is primarily clinical, relying on standardized criteria such as those outlined in the DSM-5

and ICD-10[12]**.** The lifetime risk of death by suicide in patients with schizophrenia is 5% to 10%[13]**.** Schizophrenia has unfortunately become deeply stigmatized within all societies, especially in countries like India. There are several associated disorders in the patients diagnosed with schizophrenia (Figure 4 and 5).

**Disorders associated with schizophrenia**

The data provided from Sommer et al. (2020) illustrates the spectrum of disorders associated with schizophrenia in men (Figure 3). The analysis shows a significant prevalence of affective disorders, with 39.12% of schizophrenic men experiencing these conditions. Substance use disorders are also notably high, affecting 33.58% of the population studied. Anxiety disorders are present in 10.1% of the cases, indicating a substantial overlap between schizophrenia and anxiety-related conditions. Developmental disorders, specifically ADHD, affect 9.9% of the men, while autism spectrum disorders are relatively rare, with a prevalence of 0.42%. Somatic disorders are present in 1.61% of the population, suggesting a lower but noteworthy co-occurrence with schizophrenia. Personality disorders are the least common, affecting only 0.14% of the individuals. This data underscores the complexity of schizophrenia, highlighting the diverse range of comorbid conditions that can complicate the clinical management and treatment of this mental health disorder [14].




**Figure 3 : Diagnostic proceedings showing spectrum of disorders associated with Schizophrenics in men**[14]**.**

The data on the spectrum of disorders associated with schizophrenia in women, based on the findings from Sommer et al. (2020), provides insight into the prevalence of various comorbid conditions (Figure 4). Affective disorders are strikingly prevalent among women with schizophrenia, with 62.17% experiencing these conditions, which is significantly higher compared to men. Substance use disorders, while still notable, affect 10.12% of women, indicating a lower prevalence than in men. Anxiety disorders are present in 9.9% of cases, showing a similar rate to that observed in men.

Personality disorders are more common in women with schizophrenia, affecting 12.46% of the population studied, a considerable increase compared to the male population. Somatic disorders are slightly less prevalent in women, with a rate of 1.28%. Developmental disorders, such as ADHD and autism, are relatively rare, affecting 0.06% and 0.18% of women, respectively. This data highlights the significant gender differences in the prevalence of comorbid conditions associated with schizophrenia, emphasizing the need for gender-sensitive approaches in the diagnosis and treatment of this complex mental health disorder[14].




**Figure 4: Diagnostic proceedings showing spectrum of disorders associated with Schizophrenics in women**[14]**.**

**Age-specific and sex-specific prevalence of mental disorders in India**

Figure 5 displays the age-specific and sex-specific prevalence of mental disorders in India for the year 2017. The X-axis represents age groups divided into intervals starting from under 5 years (<5), then 5-9, 10-14, and so on, up to over 80 years (>80). The Y-axis shows the prevalence as a percentage,

ranging from 0 to 0.6 (0 to 60%). The black line with circle markers represents the prevalence of mental disorders among males, while the orange line with triangle markers represents the prevalence among females.

Observations indicate that for children and adolescents (under 20 years), both males and females show a low prevalence of mental disorders, with males slightly higher than females in the 10-19 age group. Among young adults (20-34 years), there is a rapid increase in prevalence for both sexes, with males showing a steeper rise. Peak prevalence begins in the 20-24 age group for both sexes. In middle age (35-54 years), prevalence remains high, with males consistently showing higher rates than females, peaking around the 35-44 age group for both genders. For older adults (55+ years), prevalence begins to decline gradually after 55 years, with males still having higher rates compared to females until around 75 years. Both sexes show a significant drop in prevalence beyond 80 years.

Key points highlight that males reach a peak prevalence of just above 50% in the 35-44 age group, while females peak slightly lower, just below 50%, in the same age group. Across almost all age groups, males have a higher prevalence of mental disorders compared to females. Both males and females show a decline in prevalence of mental disorders starting from 55 years onwards, with a steep drop after 75 years. This chart helps in understanding the distribution of mental disorders across different age groups and sexes in India, highlighting critical age groups that may require targeted mental health interventions[15].



**Figure-5: Age-specific and sex-specific prevalence of mental disorders in India, 2017**[15]**.**

Current research implicates abnormalities in neurotransmitter systems (e.g., dopamine, glutamate), neurodevelopmental factors, and structural brain abnormalities in the pathophysiology of schizophrenia. Advances in neuroimaging techniques have offered insights into these underlying biological mechanisms. Managing schizophrenia typically involves a multimodal approach that combines antipsychotic medications, psychosocial interventions, and supportive therapies [16]. First-generation (typical) and second-generation (atypical) antipsychotics target dopaminergic pathways, while newer treatments focus on enhancing cognitive function and addressing treatment-resistant symptoms [17].

**Prevalence and Global Statistics**

Schizophrenia is a significant global health concern, with varying prevalence rates observed across different regions and populations [18]. Here's an overview of the prevalence and estimated number of cases of schizophrenia both worldwide and specifically in India:

**Worldwide Prevalence:**

Globally, schizophrenia affects approximately 20 million people. The prevalence is estimated to be around 0.3% to 0.7% of the population but the rates can vary based on factors such as urbanization, socio-economic status, and access to healthcare. Regions with higher rates include Europe and the Americas, while lower rates are typically seen in Africa and Asia.

**Prevalence in India:**

In India, the prevalence of schizophrenia is reported to be around 0.5% to 1% of the population. With India's large population, this translates to a substantial number of individuals affected by the disorder. Urban areas may have slightly higher prevalence rates compared to rural areas, influenced by factors such as stress, lifestyle changes, and access to mental health services.

**Number of Cases:**

Given the global population of approximately 7.9 billion, and assuming a conservative prevalence rate of 0.5%, there would be around 39.5 million people worldwide affected by schizophrenia. In India, with a population of over 1.3 billion, a prevalence rate of 0.5% would mean around 6.5 million people living with schizophrenia.

**Factors Influencing Prevalence:**

**Urbanization and Lifestyle:** Urban areas tend to have higher rates of schizophrenia possibly due to higher stress levels, pollution, and lifestyle changes.

**Socio-Economic Factors:** Poverty and lack of access to healthcare can impact prevalence rates.

**Cultural and Genetic Factors:** Genetic predisposition combined with cultural factors may influence susceptibility and presentation of symptoms.

**Challenges and Implications:**

Despite these estimates, there are significant challenges in accurately assessing and addressing the burden of schizophrenia due to underreporting, stigma, and varying healthcare infrastructures globally. Efforts in improving awareness, early detection, and access to treatment are crucial in reducing the personal and societal impact of schizophrenia.

Understanding the epidemiology of schizophrenia is essential for healthcare planning, resource allocation, and developing effective strategies to support individuals and families affected by this complex mental disorder across the world, including in India.

**Positive, Negative and Cognitive Symptoms**

Schizophrenia is a complex psychiatric disorder affecting approximately 1% of the global population. Understanding its symptoms is crucial for accurate diagnosis, effective treatment, and improved quality of life for affected individuals [19–22]. The symptoms of schizophrenia are categorized into three main types: positive, negative, and cognitive symptoms. Each category encompasses different aspects of the disorder and impacts individuals in unique ways.

Positive symptoms refer to abnormal mental experiences or behaviors that are added to a person's normal repertoire. These symptoms include hallucinations, delusions, and disorganized thinking. Hallucinations involve perceptions in the absence of external stimuli, commonly auditory but can also be visual, tactile, olfactory, or gustatory. Delusions are fixed false beliefs that are not consistent with the individual's cultural or educational background. Disorganized thinking manifests as fragmented thought patterns that impair logical reasoning and coherence in speech. These symptoms can be particularly distressing and disruptive, often leading to significant challenges in daily functioning.

Negative symptoms involve deficits in normal emotional and behavioral processes. Affective flattening is characterized by a reduced intensity and range of emotional expression, making individuals appear emotionally unresponsive. Alogia, or impoverished thinking, leads to diminished speech production, while avolition refers to a decreased motivation to initiate and sustain goal-directed

activities. These symptoms contribute to social withdrawal and difficulty in engaging in routine activities, profoundly affecting the quality of life.

Cognitive symptoms impact various domains of cognitive function, further complicating the lives of individuals with schizophrenia. Impaired working memory makes it difficult for individuals to hold and manipulate information over short periods. Executive dysfunction involves challenges in planning, problem-solving, and cognitive flexibility, hindering the ability to make decisions and adapt to changing situations. Attentional deficits reduce the ability to focus and sustain attention, affecting everyday tasks and learning processes. These cognitive impairments are often overlooked but are critical in understanding the full impact of schizophrenia on an individual's functioning.

Overall, the diverse range of symptoms associated with schizophrenia underscores the importance of comprehensive assessment and individualized treatment plans. By addressing positive, negative, and cognitive symptoms, healthcare professionals can better support individuals with schizophrenia, enhancing their ability to manage the disorder and improve their overall quality of life.

**Diagnostic Criteria and Assessment:** Diagnosis of schizophrenia involves assessing the presence, duration, and impact of these symptoms using standardized criteria such as those outlined in the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition) or ICD-10 (International Classification of Diseases, Tenth Revision). Clinical interviews, observations, and rating scales are utilized for comprehensive evaluation.

**Neurobiological Correlates:** Underlying neurobiological mechanisms include dysregulation of neurotransmitter systems (e.g., dopamine, glutamate), structural brain abnormalities, and neurodevelopmental factors. Advances in neuroimaging techniques have provided insights into these neural correlates [23].

**Differential Diagnosis and Comorbidities:** Distinguishing schizophrenia from other psychiatric disorders with overlapping symptoms (e.g., bipolar disorder, schizoaffective disorder) is crucial for accurate diagnosis and treatment planning. Comorbidities such as substance use disorders and medical conditions may further complicate management.

### Treatment Strategies

Schizophrenia poses significant challenges due to its chronicity, diverse symptomatology, and impact on cognitive and social functioning. Effective treatment strategies are essential to mitigate symptoms and enhance overall well-being. Treatment strategies for schizophrenia have advanced significantly,

yet challenges remain in optimizing outcomes and addressing individual needs. Continued research and innovation are critical to expanding therapeutic options, reducing stigma, and improving the lives of individuals affected by this complex mental disorder[24,25].

**Pharmacological Interventions:** Pharmacological treatment of schizophrenia involves the use of first-generation (typical) and second-generation (atypical) antipsychotics. These medications primarily target dopamine receptors to alleviate positive symptoms such as hallucinations and delusions. Common examples include haloperidol, risperidone, olanzapine, and clozapine. First-generation antipsychotics often have more extrapyramidal side effects, while second-generation antipsychotics are designed to minimize these effects and other side effects like metabolic disturbances[2].

**Psychosocial Therapies:** Cognitive Behavioral Therapy (CBT): CBT helps individuals manage symptoms by identifying and modifying dysfunctional thought patterns and behaviors. It is effective in reducing relapse rates and improving coping strategies. Family Therapy: Involves educating families about schizophrenia, improving communication, and providing support to enhance patient outcomes and family functioning. Social Skills Training: Teaches practical skills such as interpersonal communication and problem-solving to improve social interactions and functioning in daily life.

**Integrated Treatment Approaches:** Assertive Community Treatment (ACT): Multidisciplinary teams provide comprehensive support, including medication management, therapy, and social services, to individuals with severe mental illness in community settings. Supported Employment and Education: Programs assist individuals in obtaining and maintaining employment or pursuing educational goals, promoting independence and self-sufficiency.

**Novel and Emerging Treatments: Cognitive Remediation:** Targets cognitive deficits through structured exercises to improve memory, attention, and problem-solving skills. Transcranial Magnetic Stimulation (TMS): Non-invasive brain stimulation may alleviate symptoms in some individuals resistant to traditional therapies. Digital Therapeutics: Mobile apps and online platforms offer self-help tools, psychoeducation, and support for symptom management and adherence to treatment.

**Challenges in Treatment: Medication Adherence:** Many individuals with schizophrenia struggle with adherence to medication regimens due to side effects, lack of insight into their illness, or stigma associated with treatment. Treatment Resistance: A subset of patients does not respond adequately to

available medications, necessitating alternative strategies and ongoing research into novel treatments. Stigma and Social Isolation: Barriers to accessing care and achieving recovery include societal stigma and limited support networks.

**Future Directions in Research**

Future research in the field of schizophrenia is increasingly focusing on tailoring treatments based on genetic, neurobiological, and clinical factors to enhance efficacy and minimize side effects. By leveraging advances in precision medicine, scientists and clinicians are aiming to create more individualized and effective treatment plans for patients with schizophrenia. This approach promises to improve the quality of care and outcomes for individuals suffering from this complex disorder.

Neuroscience Advances

Understanding the neural circuits and molecular pathways involved in schizophrenia is critical for developing targeted interventions. Advances in neuroscience are uncovering the specific brain regions and neural connections that are affected in schizophrenia. By mapping these neural circuits and identifying the molecular pathways that contribute to the disorder, researchers can design interventions that specifically target these areas. This can lead to the development of more effective treatments with fewer side effects, ultimately improving patient outcomes[26].

Early Intervention

Promoting early detection and intervention is crucial for improving long-term outcomes in individuals with schizophrenia. Research indicates that early intervention can significantly enhance the prognosis by addressing symptoms promptly and preventing further disability. Identifying individuals at risk and providing timely treatment can mitigate the disorder's impact and improve the quality of life for patients. Early intervention strategies often include a combination of pharmacological treatments, psychotherapy, and social support services, all tailored to the individual's specific needs. For instance, the Schizophrenia Bulletin highlights the importance of focusing on the early course of schizophrenia, including detection during the prodromal phase and the implementation of early treatment interventions to enhance treatment response and prognosis[27].

The National Institute of Mental Health (NIMH) also underscores the benefits of early detection and intervention, noting that evidence-based treatments for first-episode psychosis can lead to better long-

term outcomes. These treatments typically involve coordinated specialty care, which integrates medication management, psychosocial therapies, family education and support, and case management (NIH NIMH)[28]. By emphasizing early detection and providing comprehensive, individualized care, healthcare providers can improve the prognosis for individuals with schizophrenia, reducing the severity of symptoms and enhancing overall well-being.

Precision Medicine in Schizophrenia

Precision medicine is a highly advanced approach currently used in the treatment of schizophrenia. This method involves tailoring treatment strategies to individual patients based on their unique genetic, biomarker, and clinical characteristics. The goal of this personalized approach is to maximize the efficacy of treatments while minimizing side effects.

Researchers are utilizing genetic data, including pharmacogenomics, to predict individual responses to antipsychotic medications. For instance, variations in genes related to the cytochrome P450 enzyme system, which is responsible for drug metabolism, have been shown to influence treatment outcomes and side effects. Despite the promise of pharmacogenetics, more research is needed to translate these findings into clinical practice effectively[29,30].

Furthermore, advancements in biomarkers, such as brain structure imaging and functional connectivity studies, are being integrated into precision psychiatry to better understand and treat schizophrenia. By combining genetic, molecular, and clinical data, healthcare providers can develop highly targeted and effective treatment plans[29].

Genetic Testing

Genetic testing plays a crucial role in precision medicine for schizophrenia by identifying specific genetic variations that may influence a person’s response to medications. For example, variations in genes encoding drug-metabolizing enzymes or receptors targeted by antipsychotic medications can affect how patients respond to treatment[31,32]. Understanding these genetic factors allows clinicians to select the most appropriate medications and dosages for each patient.

Biomarkers

Utilizing biomarkers from blood tests, brain imaging, or other diagnostic tools can help predict disease progression, treatment response, or potential side effects of medications. Imaging studies might reveal

specific patterns of brain activity or structure that could guide treatment decisions[33]. By incorporating biomarkers into the diagnostic and treatment process, healthcare providers can make more informed and effective treatment choices.

Personalized Treatment Plans

Developing individualized treatment plans that consider a patient's genetic profile, biomarker results, medical history, and preferences is a cornerstone of precision medicine. Personalized treatment plans may involve adjusting medication dosages, choosing between different classes of antipsychotic drugs, or incorporating non-pharmacological interventions such as cognitive behavioral therapy (CBT). This tailored approach ensures that each patient receives the most suitable and effective treatment for their specific condition.

Predictive Modeling

Predictive modeling in healthcare, particularly using data analytics and machine learning, is a powerful approach to improve patient outcomes by enabling personalized treatment recommendations. By analyzing large datasets, including electronic health records, health claims data, and other clinical information, predictive modeling can help in making accurate diagnoses and selecting the most effective treatments for individual patients.

Predictive analytics involves advanced techniques such as statistical modeling, data mining, and machine learning to predict future health outcomes based on historical data. These methods can identify patterns and trends that inform clinical decision-making and risk management, helping providers to deliver more targeted and efficient care. For example, predictive models can be used to detect and manage chronic illnesses by predicting disease progression and treatment efficacy. This approach allows healthcare professionals to tailor interventions to each patient's unique characteristics, thereby enhancing treatment outcomes and reducing adverse events. Furthermore, integrating predictive modeling into clinical workflows facilitates proactive care. It can help healthcare systems identify high-risk patients early, optimize resource allocation, and improve overall healthcare delivery by anticipating when and where care is needed[34].

### Targeted Therapies

Exploring new treatment options that target specific molecular pathways implicated in schizophrenia is another promising area of research. Targeted therapies may be more effective or have fewer side effects compared to traditional treatments. By focusing on the underlying biological mechanisms of the disorder, researchers can develop innovative treatments that offer improved efficacy and safety for patients.

### Longitudinal Monitoring

Implementing continuous monitoring of patients' symptoms, biomarkers, and treatment responses over time is essential for optimizing treatment plans. Longitudinal monitoring allows healthcare providers to adjust treatment plans as needed, ensuring that patients receive the most effective and appropriate care. This ongoing assessment helps to improve outcomes and maintain the stability of patients with schizophrenia[35].

### Ethical Considerations

Addressing ethical considerations is essential for advancing precision medicine in schizophrenia. This includes concerns about privacy related to genetic testing, the need for informed consent when using personal data for research, and ensuring equitable access to precision medicine for all patients.

One of the primary ethical challenges is maintaining patient privacy, especially with the vast amount of genetic and personal data collected. Genetic testing and the use of mobile health devices can capture extensive data, raising concerns about how this data is used and shared. Proper informed consent protocols must be established to ensure patients are fully aware of how their data will be used and the potential risks involved[36,37].

Moreover, equitable access to precision medicine is critical. Precision medicine must be accessible to all patients, not just those with the financial means or within certain demographic groups. This involves addressing biases in data collection and ensuring that underrepresented groups are included in genomic databases and research efforts. This inclusion is vital for developing treatments that are effective across diverse populations[37].

## Conclusion

Recovery in schizophrenia is a multidimensional concept, several authors have proposed that it should encompass at least two key domains: clinical remission and social functioning. Prioritizing functional outcomes in therapeutic interventions for schizophrenia is crucial. The modern methods of treatment hold the key in managing schizophrenia effectively. Therefore, measuring treatment response, remission, and functional recovery from this perspective becomes essential. Achieving improved outcomes in schizophrenia requires an integrated and comprehensive approach that includes pharmacotherapy, psychosocial interventions, and consideration of environmental factors[38].

Providing patient-centered care for individuals with schizophrenia requires an interdisciplinary approach. The healthcare team should include psychiatrists, primary care physicians, advanced practitioners, psychologists, nurses, pharmacists, vocational rehabilitation therapists, occupational therapists, and social workers. These professionals must possess a comprehensive understanding of schizophrenia's clinical aspects, encompassing diagnosis, symptom management, and the complexities of psychopharmacological and psychotherapeutic treatments. This expertise is crucial for interpreting psychiatric assessments, identifying a broad spectrum of symptoms, and navigating the challenges presented by both acute and chronic phases of schizophrenia.

Ethical considerations are paramount in treating schizophrenia, particularly in upholding patient autonomy and ensuring informed consent for treatment plans. Interprofessional collaboration is essential, with each team member contributing specialized knowledge and skills to optimize patient care. Effective communication within the team is critical to fostering an environment where information is openly shared, concerns are promptly addressed, and patient-centered strategies are collaboratively developed. Physicians, advanced practitioners, nurses, pharmacists, and other healthcare professionals must collaborate seamlessly to support the patient's journey from diagnosis through treatment and follow-up care. This coordinated approach helps minimize treatment errors, reduce care delays, and enhance overall patient safety. Ultimately, this comprehensive care approach leads to improved outcomes and emphasizes patient-centered care that supports the recovery of individuals living with schizophrenia.

**Conflicts of interest:** The author has no conflicts of interest relevant to this article.

**Funding source:** This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Figure Captions:**

Figure 1: Age at onset distribution of Schizophrenia in years

Figure 2: Estimated share of people who had schizophrenia in the past year in the nations with highest prevelance

Figure 3 : Diagnostic proceedings showing spectrum of disorders associated with Schizophrenics in men

Figure 4: Diagnostic proceedings showing spectrum of disorders associated with Schizophrenics in women

Figure-5: Age-specific and sex-specific prevalence of mental disorders in India, 2017

**References**

[1] World Health Organization, (n.d.). https://www.who.int/news-room/fact-sheets/detail/schizophrenia.

[2] R. O'Carroll, Cognitive impairment in schizophrenia, Adv. Psychiatr. Treat 6 (2000) 161–168. https://doi.org/10.1192/apt.6.3.161.

[3] M. Chokshi, B. Patil, R. Khanna, S.B. Neogi, J. Sharma, V.K. Paul, S. Zodpey, Health systems in India, J Perinatol 36 (2016) S9–S12. https://doi.org/10.1038/jp.2016.184.

[4] H.H. Kyu, D. Abate, K.H. Abate, S.M. Abay, C. Abbafati, N. Abbasi, H. Abbastabar, F. Abd-Allah, J. Abdela, A. Abdelalim, I. Abdollahpour, R.S. Abdulkader, M. Abebe, Z. Abebe, O.Z. Abil, V. Aboyans, A.R. Abrham, L.J. Abu-Raddad, N.M.E. Abu-Rmeileh, M.M.K. Accrombessi, D. Acharya, P. Acharya, I.N. Ackerman, A.A. Adamu, O.M. Adebayo, V. Adekanmbi, Z. Ademi, O.O. Adetokunboh, M.G. Adib, J.C. Adsuar, K.A. Afanvi, M. Afarideh, A. Afshin, G. Agarwal, K.M. Agesa, R. Aggarwal, S.A. Aghayan, A. Agrawal, A. Ahmadi, M. Ahmadi, H. Ahmadieh, M.B. Ahmed, S. Ahmed, A.N. Aichour, I. Aichour, M.T.E. Aichour, T. Akinyemiju, N. Akseer, Z. Al-Aly, A. Al-Eyadhy, H.M. Al-Mekhlafi, R.M. Al-Raddadi, F. Alahdab, K. Alam, T. Alam, A. Alashi, S.M. Alavian, K.A. Alene, M. Alijanzadeh, R. Alizadeh-Navaei, S.M. Aljunid, A. Alkerwi, F. Alla, P. Allebeck, J. Alonso, U. Alsharif, K. Altirkawi, N. Alvis-Guzman, L.N. Aminde, E. Amini, M. Amiresmaili, W. Ammar, Y.A.

Amoako, N.H. Anber, C.L. Andrei, S. Androudi, M.D. Animut, M. Anjomshoa, M.G. Ansha, C.A.T. Antonio, P. Anwari, J. Arabloo, O. Aremu, J. Ärnlöv, A. Arora, M. Arora, A. Artaman, K.K. Aryal, H. Asayesh, Z. Ataro, M. Ausloos, L. Avila-Burgos, E.F.G.A. Avokpaho, A. Awasthi, B.P. Ayala Quintanilla, R. Ayer, P.S. Azzopardi, A. Babazadeh, H. Badali, K. Balakrishnan, A.G. Bali, M. Banach, J.A.M. Banoub, A. Barac, M.A. Barboza, S.L. Barker-Collo, T.W. Bärnighausen, S. Barquera, L.H. Barrero, S. Bazargan-Hejazi, N. Bedi, E. Beghi, M. Behzadifar, M. Behzadifar, B.B. Bekele, E.T. Bekru, A.B. Belachew, Y.A. Belay, M.L. Bell, A.K. Bello, D.A. Bennett, I.M. Bensenor, A. Berhane, E. Bernabe, R.S. Bernstein, M. Beuran, T. Beyranvand, N. Bhala, S. Bhatt, S. Bhaumik, Z.A. Bhutta, B. Biadgo, M.H. Biehl, A. Bijani, B. Bikbov, V. Bilano, N. Bililign, M.S. Bin Sayeed, D. Bisanzio, T. Bjørge, A. Bleyer, E.M. Bobasa, I.R. Bou-Orm, S. Boufous, R. Bourne, O.J. Brady, L.C. Brant, C. Brayne, A. Brazinova, N.J.K. Breitborde, H. Brenner, P.S. Briant, A.N. Briko, G. Britton, T. Brugha, R. Buchbinder, R. Busse, Z.A. Butt, L. Cahuana-Hurtado, J.C. Campuzano Rincon, J. Cano, R. Cárdenas, J.J. Carrero, A. Carter, F. Carvalho, C.A. Castañeda-Orjuela, J. Castillo Rivas, F. Castro, F. Catalá-López, K.M. Cercy, E. Cerin, Y. Chaiah, J.-C. Chang, F.J. Charlson, V.K. Chattu, P.P.-C. Chiang, A. Chitheer, J.-Y.J. Choi, H. Christensen, D.J. Christopher, S.-C. Chung, F.M. Cicuttini, M. Cirillo, D. Collado-Mateo, C. Cooper, P.A. Cortesi, M. Cortinovis, E. Cousin, M.H. Criqui, E.A. Cromwell, M. Cross, J.A. Crump, A.K. Daba, B.A. Dachew, A.F. Dadi, L. Dandona, R. Dandona, P.I. Dargan, A. Daryani, R. Das Gupta, J. Das Neves, T.T. Dasa, D.V. Davitoiu, F.P. De La Hoz, D. De Leo, J.-W. De Neve, H. De Steur, M.G. Degefa, L. Degenhardt, S. Deiparine, G.T. Demoz, E. Denova-Gutiérrez, K. Deribe, N. Dervenis, D.C. Des Jarlais, S. Dey, S.D. Dharmaratne, M. Dhimal, M.T. Dinberu, M.A. Dirac, S. Djalalinia, L. Doan, K. Dokova, D.T. Doku, E.R. Dorsey, K.E. Doyle, T.R. Driscoll, M. Dubey, E. Dubljanin, E.E. Duken, B.B. Duncan, A.R. Duraes, H. Ebrahimi, S. Ebrahimpour, M.M. Echko, D. Edessa, D. Edvardsson, A. Effiong, A.E. Eggen, J.R. Ehrlich, C. El Bcheraoui, Z. El-Khatib, I.R.F. Elyazar, A. Enayati, M.L. Endalifer, A.Y. Endries, B. Er, H.E. Erskine, S. Eskandarieh, A. Esteghamati, S. Esteghamati, H. Fakhim, M. Faramarzi, M. Fareed, F. Farhadi, T.A. Farid, C.S.E.S. Farinha, A. Farioli, A. Faro, F. Farzadfar, A.A. Fazaeli, V.L. Feigin, N. Fentahun, S.-M. Fereshtehnejad, E. Fernandes, J.C. Fernandes, A.J. Ferrari, M.L. Ferreira, I. Filip, F. Fischer, C. Fitzmaurice, N.A. Foigt, K.J. Foreman, T.D. Frank, T. Fukumoto, N. Fullman, T. Fürst, J.M. Furtado, E. Gakidou, S. Gall, S. Gallus, M. Ganji, A.L. Garcia-Basteiro, W.M. Gardner, A.K. Gebre, A.T. Gebremedhin, T.G. Gebremichael, T.F. Gelano, J.M. Geleijnse, R. Genova-Maleras, Y.C.D. Geramo, P.W. Gething, K.E. Gezae, M.R. Ghadami, K. Ghadiri, M. Ghasemi-Kasman, M. Ghimire, A.G.

Ghoshal, P.S. Gill, T.K. Gill, I.A. Ginawi, G. Giussani, E.V. Gnedovskaya, E.M. Goldberg, S. Goli, H. Gómez-Dantés, P.N. Gona, S.V. Gopalani, T.M. Gorman, A.C. Goulart, B.N.G. Goulart, A. Grada, G. Grosso, H.C. Gugnani, F. Guillemin, Y. Guo, P.C. Gupta, R. Gupta, R. Gupta, T. Gupta, R.A. Gutiérrez, B. Gyawali, J.A. Haagsma, V. Hachinski, N. Hafezi-Nejad, H. Haghparast Bidgoli, T.B. Hagos, T.T. Hailegiyorgis, A. Haj-Mirzaian, A. Haj-Mirzaian, R.R. Hamadeh, S. Hamidi, A.J. Handal, G.J. Hankey, Y. Hao, H.L. Harb, S. Harikrishnan, H. Haririan, J.M. Haro, H. Hassankhani, H.Y. Hassen, R. Havmoeller, R.J. Hay, S.I. Hay, A. Hedayatizadeh-Omran, B. Heibati, D. Hendrie, A. Henok, I. Heredia-Pi, C. Herteliu, F. Heydarpour, P. Heydarpour, D.T. Hibstu, H.W. Hoek, H.J. Hoffman, M.K. Hole, E. Homaie Rad, P. Hoogar, H.D. Hosgood, S.M. Hosseini, M. Hosseinzadeh, M. Hostiuc, S. Hostiuc, P.J. Hotez, D.G. Hoy, M. Hsairi, A.S. Htet, J.J. Huang, K.M. Iburg, C.T. Ikeda, O.S. Ilesanmi, S.S.N. Irvani, C.M.S. Irvine, S.M.S. Islam, F. Islami, K.H. Jacobsen, L. Jahangiry, N. Jahanmehr, S.K. Jain, M. Jakovljevic, S.L. James, A.U. Jayatilleke, P. Jeemon, R.P. Jha, V. Jha, J.S. Ji, C.O. Johnson, J.B. Jonas, J. Jonnagaddala, Z. Jorjoran Shushtari, A. Joshi, J.J. Jozwiak, S.B. Jungari, M. Jürisson, Z. Kabir, R. Kadel, A. Kahsay, R. Kalani, T. Kanchan, C. Kar, M. Karami, B. Karami Matin, A. Karch, C. Karema, N. Karimi, S.M. Karimi, A. Kasaeian, D.H. Kassa, G.M. Kassa, T.D. Kassa, N.J. Kassebaum, S.V. Katikireddi, A. Kaul, N. Kawakami, Z. Kazemi, A.K. Karyani, M.M. Keighobadi, P.N. Keiyoro, L. Kemmer, G.R. Kemp, A.P. Kengne, A. Keren, Y.S. Khader, B. Khafaei, M.A. Khafaie, A. Khajavi, N. Khalid, I.A. Khalil, E.A. Khan, M.S. Khan, M.A. Khan, Y.-H. Khang, M.M. Khater, M. Khazaei, A.T. Khoja, A. Khosravi, M.H. Khosravi, A.A. Kiadaliri, Z.T. Kidanemariam, D.N. Kiirithio, C.-I. Kim, D. Kim, Y.-E. Kim, Y.J. Kim, R.W. Kimokoti, Y. Kinfu, A. Kisa, K. Kissimova-Skarbek, A.K.S. Knudsen, J.M. Kocarnik, S. Kochhar, Y. Kokubo, T. Kolola, J.A. Kopec, S. Kosen, G.A. Kotsakis, P.A. Koul, A. Koyanagi, K. Krishan, S. Krishnaswami, K.J. Krohn, B. Kuate Defo, B. Kucuk Bicer, G.A. Kumar, M. Kumar, I. Kuzin, D.P. Lad, S.D. Lad, A. Lafranconi, R. Lalloo, T. Lallukka, F.H. Lami, J.J. Lang, S.M. Langan, V.C. Lansingh, A. Latifi, K.M.-M. Lau, J.V. Lazarus, J.L. Leasher, J.R. Ledesma, P.H. Lee, J. Leigh, M. Leili, C.T. Leshargie, J. Leung, M. Levi, S. Lewycka, S. Li, Y. Li, X. Liang, Y. Liao, M.L. Liben, L.-L. Lim, S.S. Lim, M.A. Limenih, S. Linn, S. Liu, K.J. Looker, A.D. Lopez, S. Lorkowski, P.A. Lotufo, R. Lozano, T.C.D. Lucas, R. Lunevicius, R.A. Lyons, S. Ma, E.R.K. Macarayan, M.T. Mackay, E.R. Maddison, F. Madotto, D.P. Maghavani, H.T. Mai, M. Majdan, R. Majdzadeh, A. Majeed, R. Malekzadeh, D.C. Malta, A.A. Mamun, A.-L. Manda, H. Manguerra, M.A. Mansournia, A.M. Mantilla Herrera, L.G. Mantovani, J.C. Maravilla, W. Marcenes, A. Marks, F.R. Martins-Melo, I. Martopullo, W. März, M.B. Marzan, J.

Massano, B.B. Massenburg, M.R. Mathur, P.K. Maulik, M. Mazidi, C. McAlinden, J.J. McGrath, M. McKee, B.J. McMahon, S. Mehata, R. Mehrotra, K.M. Mehta, V. Mehta, F. Mejia-Rodriguez, T. Mekonen, A. Melese, M. Melku, P.T.N. Memiah, Z.A. Memish, W. Mendoza, G. Mengistu, G.A. Mensah, S.T. Mereta, A. Meretoja, T.J. Meretoja, T. Mestrovic, B. Miazgowski, T. Miazgowski, A.I. Millear, T.R. Miller, G.K. Mini, M. Mirarefin, A. Mirica, E.M. Mirrakhimov, A.T. Misganaw, P.B. Mitchell, H. Mitiku, B. Moazen, B. Mohajer, K.A. Mohammad, M. Mohammadi, N. Mohammadifard, M. Mohammadnia-Afrouzi, M.A. Mohammed, S. Mohammed, F. Mohebi, A.H. Mokdad, M. Molokhia, L. Monasta, J.C. Montañez, M. Moosazadeh, G. Moradi, M. Moradi, M. Moradi-Lakeh, M. Moradinazar, P. Moraga, L. Morawska, I. Moreno Velásquez, J. Morgado-Da-Costa, S.D. Morrison, M.M. Moschos, S.M. Mousavi, K.B. Mruts, A.A. Muche, K.F. Muchie, U.O. Mueller, O.S. Muhammed, S. Mukhopadhyay, K. Muller, J.E. Mumford, G.V.S. Murthy, K.I. Musa, G. Mustafa, A.F. Nabhan, C. Nagata, G. Nagel, M. Naghavi, A. Naheed, A. Nahvijou, G. Naik, F. Najafi, H.S. Nam, V. Nangia, J.R. Nansseu, N. Neamati, I. Negoi, R.I. Negoi, S. Neupane, C.R.J. Newton, J.W. Ngunjiri, A.Q. Nguyen, G. Nguyen, H.T. Nguyen, H.L.T. Nguyen, H.T. Nguyen, L.H. Nguyen, M. Nguyen, N.B. Nguyen, S.H. Nguyen, E. Nichols, D.N.A. Ningrum, M.R. Nixon, S. Nomura, M. Noroozi, B. Norrving, J.J. Noubiap, H.R. Nouri, M.N. Shiadeh, M.R. Nowroozi, E.O. Nsoesie, P.S. Nyasulu, C.M. Odell, R. Ofori-Asenso, F.A. Ogbo, I.-H. Oh, O. Oladimeji, A.T. Olagunju, T.O. Olagunju, P.R. Olivares, H.E. Olsen, B.O. Olusanya, J.O. Olusanya, K.L. Ong, S.K. Ong, E. Oren, A. Ortiz, E. Ota, S.S. Otstavnov, S. Øverland, M.O. Owolabi, M. P A, R. Pacella, A.P. Pakhare, A.H. Pakpour, A. Pana, S. Panda-Jonas, E.-K. Park, J. Park, C.D.H. Parry, H. Parsian, Y. Pasdar, S. Patel, S.T. Patil, A. Patle, G.C. Patton, V.R. Paturi, D. Paudel, K.R. Paulson, N. Pearce, A. Pereira, D.M. Pereira, N. Perico, K. Pesudovs, M. Petzold, H.Q. Pham, M.R. Phillips, D.M. Pigott, J.D. Pillay, M.A. Piradov, M. Pirsaheb, F. Pishgar, O. Plana-Ripoll, S. Polinder, S. Popova, M.J. Postma, A. Pourshams, H. Poustchi, D. Prabhakaran, S. Prakash, V. Prakash, N. Prasad, C.A. Purcell, M. Qorbani, D.A. Quistberg, A. Radfar, A. Rafay, A. Rafiei, F. Rahim, K. Rahimi, Z. Rahimi, A. Rahimi-Movaghar, V. Rahimi-Movaghar, M. Rahman, M.H.U. Rahman, M.A. Rahman, S.U. Rahman, R.K. Rai, F. Rajati, P. Ranjan, P.C. Rao, D. Rasella, D.L. Rawaf, S. Rawaf, K.S. Reddy, R.C. Reiner, M.B. Reitsma, G. Remuzzi, A.M.N. Renzaho, S. Resnikoff, S. Rezaei, M.S. Rezai, A.L.P. Ribeiro, N.L.S. Roberts, S.R. Robinson, L. Roever, L. Ronfani, G. Roshandel, A. Rostami, G.A. Roth, D. Rothenbacher, E. Rubagotti, P.S. Sachdev, N. Sadat, E. Sadeghi, S. Saeedi Moghaddam, H. Safari, Y. Safari, R. Safari-Faramani, M. Safdarian, S. Safi, S. Safiri, R. Sagar, A. Sahebkar, M.A. Sahraian, H.S. Sajadi, N.

Salam, J.S. Salama, P. Salamati, Z. Saleem, Y. Salimi, H. Salimzadeh, J.A. Salomon, S.S. Salvi, I. Salz, A.M. Samy, J. Sanabria, M.D. Sanchez-Niño, D.F. Santomauro, I.S. Santos, J.V. Santos, M.M. Santric Milicevic, B.P. Sao Jose, M. Sardana, A.R. Sarker, R. Sarmiento-Suárez, N. Sarrafzadegan, B. Sartorius, S. Sarvi, B. Sathian, M. Satpathy, A.R. Sawant, M. Sawhney, S. Saxena, E. Schaeffner, M.I. Schmidt, I.J.C. Schneider, A.E. Schutte, D.C. Schwebel, F. Schwendicke, J.G. Scott, M. Sekerija, S.G. Sepanlou, E. Serván-Mori, S. Seyedmousavi, H. Shabaninejad, A. Shafieesabet, M. Shahbazi, A.A. Shaheen, M.A. Shaikh, M. Shams-Beyranvand, M. Shamsi, H. Sharafi, K. Sharafi, M. Sharif, M. Sharif-Alhoseini, J. Sharma, R. Sharma, J. She, A. Sheikh, P. Shi, K. Shibuya, M.S. Shiferaw, M. Shigematsu, R. Shiri, R. Shirkoohi, I. Shiue, Y. Shokoohinia, F. Shokraneh, H. Shoman, M.G. Shrime, S. Si, S. Siabani, A.M. Sibai, T.J. Siddiqi, I.D. Sigfusdottir, R. Sigurvinsdottir, D.A.S. Silva, J.P. Silva, D.G.A. Silveira, N.S.V. Singam, J.A. Singh, N.P. Singh, V. Singh, D.N. Sinha, E. Skiadaresi, V. Skirbekk, K. Sliwa, D.L. Smith, M. Smith, A.M. Soares Filho, B.H. Sobaih, S. Sobhani, M. Soofi, R.J.D. Sorensen, J.B. Soriano, I.N. Soyiri, L.A. Sposato, C.T. Sreeramareddy, V. Srinivasan, J.D. Stanaway, V.I. Starodubov, D.J. Stein, C. Steiner, T.J. Steiner, M.A. Stokes, L.J. Stovner, M.L. Subart, A. Sudaryanto, M.B. Sufiyan, G. Sulo, B.F. Sunguya, P.J. Sur, B.L. Sykes, P.N. Sylaja, D.O. Sylte, C.E.I. Szoeke, R. Tabarés-Seisdedos, T. Tabuchi, S.K. Tadakamadla, N. Tandon, S.G. Tassew, M. Tavakkoli, N. Taveira, H.R. Taylor, A. Tehrani-Banihashemi, T.G. Tekalign, S.W. Tekelemedhin, M.G. Tekle, M.-H. Temsah, O. Temsah, A.S. Terkawi, B. Tessema, M. Teweldemedhin, K.R. Thankappan, A. Theis, S. Thirunavukkarasu, N. Thomas, B. Tilahun, Q.G. To, M. Tonelli, R. Topor-Madry, A.E. Torre, M. Tortajada-Girbés, M. Touvier, M.R. Tovani-Palone, J.A. Towbin, B.X. Tran, K.B. Tran, C.E. Troeger, A.G. Tsadik, D. Tsoi, L. Tudor Car, S. Tyrovolas, K.N. Ukwaja, I. Ullah, E.A. Undurraga, R.L. Updike, M.S. Usman, O.A. Uthman, M. Vaduganathan, A. Vaezi, P.R. Valdez, E. Varavikova, S. Varughese, T.J. Vasankari, N. Venketasubramanian, S. Villafaina, F.S. Violante, S.K. Vladimirov, V. Vlassov, S.E. Vollset, T. Vos, K. Vosoughi, I.S. Vujcic, F.S. Wagnew, Y. Waheed, Y. Wang, Y.-P. Wang, E. Weiderpass, R.G. Weintraub, D.J. Weiss, F. Weldegebreal, K.G. Weldegwergs, A. Werdecker, T.E. West, R. Westerman, H.A. Whiteford, J. Widecka, T. Wijeratne, H.C. Williams, L.B. Wilner, S. Wilson, A.S. Winkler, A.B. Wiyeh, C.S. Wiysonge, C.D.A. Wolfe, A.D. Woolf, G.M.A. Wyper, D. Xavier, G. Xu, S. Yadgir, S.H. Yahyazadeh Jabbari, T. Yamada, L.L. Yan, Y. Yano, M. Yaseri, Y.J. Yasin, A. Yeshaneh, E.M. Yimer, P. Yip, E. Yisma, N. Yonemoto, S.-J. Yoon, M. Yotebieng, M.Z. Younis, M. Yousefifard, C. Yu, V. Zadnik, Z. Zaidi, S.B. Zaman, M. Zamani, H. Zandian, H.J. Zar, Z.M. Zenebe, M. Zhou, B. Zipkin, S. Zodpey, I. Zucker, L.J. Zuhlke, C.J.L. Murray, Global, regional,

and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017, The Lancet 392 (2018) 1859–1922. https://doi.org/10.1016/S0140-6736(18)32335-3.

[5] World Health Organization, Mental health action plan 2013-2020, World Health Organization, Geneva, 2013. https://iris.who.int/handle/10665/89966 (accessed August 13, 2024).

[6] S.R. Marder, T.D. Cannon, Schizophrenia, N Engl J Med 381 (2019) 1753–1761. https://doi.org/10.1056/NEJMra1808803.

[7] P.C. Sham, C.J. MacLean, K.S. Kendler, A typological model of schizophrenia based on age at onset, sex and familial morbidity, Acta Psychiatr Scand 89 (1994) 135–141. https://doi.org/10.1111/j.1600-0447.1994.tb01501.x.

[8] IHME, Global Burden of Disease (2024) – with major processing by Our World in Data, (n.d.). https://ourworldindata.org/grapher/schizophrenia-prevalence.

[9] R.S. Kahn, On the Origins of Schizophrenia, AJP 177 (2020) 291–297. https://doi.org/10.1176/appi.ajp.2020.20020147.

[10] M.J. Owen, A. Sawa, P.B. Mortensen, Schizophrenia, The Lancet 388 (2016) 86–97. https://doi.org/10.1016/S0140-6736(15)01121-6.

[11] Schizophrenia - National Institute of Mental Health (NIMH), (n.d.). https://www.nimh.nih.gov/health/statistics/schizophrenia (accessed August 13, 2024).

[12] F. Biedermann, W.W. Fleischhacker, Psychotic disorders in DSM-5 and ICD-11, CNS Spectr. 21 (2016) 349–354. https://doi.org/10.1017/S1092852916000316.

[13] R.A. McCutcheon, T. Reis Marques, O.D. Howes, Schizophrenia—An Overview, JAMA Psychiatry 77 (2020) 201. https://doi.org/10.1001/jamapsychiatry.2019.3360.

[14] I.E. Sommer, J. Tiihonen, A. Van Mourik, A. Tanskanen, H. Taipale, The clinical course of schizophrenia in women and men—a nation-wide cohort study, Npj Schizophr 6 (2020) 12. https://doi.org/10.1038/s41537-020-0102-z.

[15] R. Sagar, R. Dandona, G. Gururaj, R.S. Dhaliwal, A. Singh, A. Ferrari, T. Dua, A. Ganguli, M. Varghese, J.K. Chakma, G.A. Kumar, K.S. Shaji, A. Ambekar, T. Rangaswamy, L. Vijayakumar, V. Agarwal, R.P. Krishnankutty, R. Bhatia, F. Charlson, N. Chowdhary, H.E. Erskine, S.D. Glenn, V. Krish, A.M. Mantilla Herrera, P. Mutreja, C.M. Odell, P.K. Pal, S. Prakash, D. Santomauro, D.K. Shukla, R. Singh, R.K.L. Singh, J.S. Thakur, A.S. ThekkePurakkal, C.M. Varghese, K.S. Reddy, S.

Swaminathan, H. Whiteford, H.J. Bekedam, C.J.L. Murray, T. Vos, L. Dandona, The burden of mental disorders across the states of India: the Global Burden of Disease Study 1990–2017, The Lancet Psychiatry 7 (2020) 148–161. https://doi.org/10.1016/S2215-0366(19)30475-4.

[16] K. Hashimoto, Recent Advances in the Early Intervention in Schizophrenia: Future Direction from Preclinical Findings, Curr Psychiatry Rep 21 (2019) 75. https://doi.org/10.1007/s11920-019-1063-7.

[17] J. Paris, Differential Diagnosis of Borderline Personality Disorder, Psychiatric Clinics of North America 41 (2018) 575–582. https://doi.org/10.1016/j.psc.2018.07.001.

[18] J. Van De Leemput, J.L. Hess, S.J. Glatt, M.T. Tsuang, Genetics of Schizophrenia, in: Advances in Genetics, Elsevier, 2016: pp. 99–141. https://doi.org/10.1016/bs.adgen.2016.08.001.

[19] S.R. Marder, B. Kirkpatrick, Defining and measuring negative symptoms of schizophrenia in clinical trials, European Neuropsychopharmacology 24 (2014) 737–743. https://doi.org/10.1016/j.euroneuro.2013.10.016.

[20] M. Adida, J.-M. Azorin, R. Belzeaux, E. Fakra, Symptômes négatifs : clinique et psychométrie, L'Encéphale 41 (2015) 6S15-6S17. https://doi.org/10.1016/S0013-7006(16)30004-5.

[21] J. Davis, H. Eyre, F.N. Jacka, S. Dodd, O. Dean, S. McEwen, M. Debnath, J. McGrath, M. Maes, P. Amminger, P.D. McGorry, C. Pantelis, M. Berk, A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis, Neuroscience & Biobehavioral Reviews 65 (2016) 185–194. https://doi.org/10.1016/j.neubiorev.2016.03.017.

[22] B. Batinic, COGNITIVE MODELS OF POSITIVE AND NEGATIVE SYMPTOMS OF SCHIZOPHRENIA AND IMPLICATIONS FOR TREATMENT, 31 (n.d.).

[23] S.K. Kar, M. Jain, Current understandings about cognition and the neurobiological correlates in schizophrenia, Journal of Neurosciences in Rural Practice 07 (2016) 412–418. https://doi.org/10.4103/0976-3147.176185.

[24] D.C. Javitt, Balancing therapeutic safety and efficacy to improve clinical and economic outcomes in schizophrenia: a clinical overview, Am J Manag Care 20 (2014) S160-165.

[25] P. Stępnicki, M. Kondej, A.A. Kaczor, Current Concepts and Treatments of Schizophrenia, Molecules 23 (2018) 2087. https://doi.org/10.3390/molecules23082087.

[26] C. Deng, B. Dean, eds., Mapping the pathophysiology of schizophrenia: interactions between multiple cellular pathways, Frontiers Media SA, 2014. https://doi.org/10.3389/978-2-88919-199-4.

[27] T.H. McGlashan, Early Detection and Intervention in Schizophrenia: Research, Schizophrenia Bulletin 22 (1996) 327–345. https://doi.org/10.1093/schbul/22.2.327.

[28] Robert K. Heinssen,Amy B. GoldsteinSusan T. Azrin, Balancing Therapeutic Safety and Efficacy to Improve Clinical and Economic Outcomes in Schizophrenia: A Clinical Overview, (2014).

[29] C. Jones, C.B. Nemeroff, Precision Psychiatry: Biomarker-Guided Tailored Therapy for Effective Treatment and Prevention in Major Depression, in: Y.-K. Kim (Ed.), Major Depressive Disorder, Springer Singapore, Singapore, 2021: pp. 535–563. https://doi.org/10.1007/978-981-33-6044-0_27.

[30] J. Lally, J.H. MacCabe, Personalised approaches to pharmacotherapy for schizophrenia, BJPsych Advances 22 (2016) 78–86. https://doi.org/10.1192/apt.bp.114.013433.

[31] M. Karayiorgou, J.A. Gogos, A Turning Point in Schizophrenia Genetics, Neuron 19 (1997) 967–979. https://doi.org/10.1016/S0896-6273(00)80390-6.

[32] The Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium, Genome-wide association study identifies five new schizophrenia loci, Nat Genet 43 (2011) 969–976. https://doi.org/10.1038/ng.940.

[33] M. Perkovic, G. Erjavec, D. Strac, S. Uzun, O. Kozumplik, N. Pivac, Theranostic Biomarkers for Schizophrenia, IJMS 18 (2017) 733. https://doi.org/10.3390/ijms18040733.

[34] I. Rahman, AI-powered Personalized Treatment Recommendation Framework for Improved Healthcare Outcomes, JCSD 8 (2023) 42–51.

[35] J. Guo, C. He, H. Song, H. Gao, S. Yao, S.-S. Dong, T.-L. Yang, Unveiling Promising Neuroimaging Biomarkers for Schizophrenia Through Clinical and Genetic Perspectives, Neurosci. Bull. (2024). https://doi.org/10.1007/s12264-024-01214-1.

[36] S. Daws, Ethical Application of Precision Medicine to Schizophrenia Management, The New Bioethics 23 (2017) 147–153. https://doi.org/10.1080/20502877.2017.1358931.

[37] How Stratification Unites Ethical Issues in Precision Health, AMA Journal of Ethics 20 (2018) E798-803. https://doi.org/10.1001/amajethics.2018.798.

[38] A. Vita, S. Barlati, Recovery from schizophrenia: is it possible?, Current Opinion in Psychiatry 31 (2018) 246–255. https://doi.org/10.1097/YCO.0000000000000407.